DIAGNOS Announces the Appointment of Mr. Riadh Kobbi as Vice President Business Intelligence
June 04 2019 - 9:00AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK),
(OTCQB: DGNOD), a leader in early detection of critical health
issues through the use of Artificial Intelligence (AI), announces
today the appointment of Riadh Kobbi as Vice President Business
Intelligence.
Riadh has more than 20 years of international
experience in the statistics field applied to computer software,
having occupied executive roles in companies located in France,
Turkey, Morocco and Cyprus. Riadh is one the first graduates of the
master program in Business Intelligence at HEC Montreal. “After
more than a decade at DIAGNOS in the development of expertise in
predictive analytics and modeling, I am extremely proud to accept
this new role and take on this new challenge along with my
teammates dedicated to the success of DIAGNOS”, said Riadh
Kobbi.
“We are very proud to have Riadh at DIAGNOS. He
has been with our team for 14 years and has always been a creative
and a positive employee, even throughout difficult times. We are
looking forward to Riadh’s new position and are confident he will
lead our technical team towards a successful future”, said André
Larente, CEO of DIAGNOS.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America, is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS IncTel:
450-678-8882 ext. 224alarente@diagnos.ca
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements.DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024